Sign in

LFCR on Nasdaq

LIFECORE BIOMEDICAL, INC. \DE\

American pharmaceutical preparations company, incorporated in Delaware1

In its 2025 annual report the company says: “We manufacture HA in bulk form as well as for use in formulated and filled syringes and vials for our customers’ injectable products used in treating a broad spectrum of medical conditions and procedures, including ophthalmic and orthopedic applications. We have leveraged this expertise in HA fermentation, manufacturing and aseptic formulation and filling to also develop highly viscous non-HA-based sterile injectable products with our customers for multiple applications.”5 It is headquartered in Chaska, Minnesota.1 Its shares trade on Nasdaq under the symbol LFCR.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$128.9MRevenue, fiscal 20252
-$38.7MNet income, fiscal 20252

Compare with Xencor Inc, ASCENTAGE PHARMA GROUP INTERNATIONAL or GYRE THERAPEUTICS, INC., or pick any stock.

  • TickerLFCR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersChaska, Minnesota1
  • Incorporated inDE3
  • Business address3515 Lyman Boulevard, Chaska, Mn 553183
  • Filer categoryAccelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities. Lifecore has become a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (“HA”) using our proprietary, fermentation-based HA process that we developed in 1981. We manufacture HA in bulk form as well as for use in formulated and filled syringes and vials for our customers’ injectable products used in treating a broad spectrum of medical conditions an…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

31.3%Gross margin2
-13.4%Operating margin2
-30.0%Net margin2
0.5%Revenue growth, 20252
-2898.0%Return on equity2
97.63×Debt to equity2
-$13.6MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Contract Development and Manufacturing Organization brought in 70% of the revenue LIFECORE BIOMEDICAL, INC. \DE\ broke down this way in fiscal 2025.

  1. Contract Development and Manufacturing Organization$90.1M670%down 7% from 2024
  2. HA Manufacturing$38.8M630%up 23% from 2024
Products and services by year
Products and services20242025
Contract Development and Manufacturing Organization$96.6M$90.1M
HA Manufacturing$31.6M$38.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue63¢$88.6M
  • Research and development6¢$8.3M
  • Selling, general and admin31¢$44.0M
  • Income tax0¢$43.0K

Out of $128.9M in revenue.2 The company lost money this year.

Financial statements

Revenue789102$128.9M in 2025−75% since 2018
0$200.0M$400.0M$600.0M2018: $524.2M$524.2M20182019: $557.6M$557.6M2019+6%2020: $160.1M$160.1M2020−71%2021: $100.9M$100.9M2021−37%2022: $111.3M$111.3M2022+10%2023: $103.3M$103.3M2023−7%2024: $128.3M$128.3M2024+24%2025: $128.9M$128.9M2025+0%
Gross profit111289102$40.3M in 2025−49% since 2018
0$25.0M$50.0M$75.0M$100.0M2018: $78.3M$78.3M20182019: $81.0M$81.0M2019+3%2020: $39.4M$39.4M2020−51%2021: $38.9M$38.9M2021−1%2022: $39.1M$39.1M2022+0%2023: $28.0M$28.0M2023−28%2024: $41.9M$41.9M2024+50%2025: $40.3M$40.3M2025−4%
Operating income111289102-$17.2M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M$20.0M2018: $13.6M$13.6M20182019: $5.5M$5.5M2019−60%2020: -$25.9M-$25.9M20202021: -$8.8M-$8.8M2021−66%2022: -$11.8M-$11.8M2022+34%2023: -$21.8M-$21.8M2023+85%2024: -$8.8M-$8.8M2024−59%2025: -$17.2M-$17.2M2025+95%
Net income111289102-$38.7M in 2025
-$150.0M-$100.0M-$50.0M0$50.0M2018: $24.8M$24.8M20182019: $411.0K$411.0K2019−98%2020: -$38.2M-$38.2M20202021: -$32.3M-$32.3M2021−15%2022: -$116.7M-$116.7M2022+261%2023: -$99.6M-$99.6M2023−15%2024: $12.0M$12.0M20242025: -$38.7M-$38.7M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-05-312024-05-31
Revenues$128.9M$128.3M
Cost of sales$88.6M$86.4M
Gross profit$40.3M$41.9M
Research and development expenses$8.3M$8.6M
Selling, general, and administrative expenses$44.0M$40.5M
Loss on sale or disposal of assets, net of portion classified as cost of sales$7.0M$0
Restructuring (recovery) costs-$1.7M$1.7M
Operating loss-$17.2M-$8.8M
Interest income$333.0K$58.0K
Change in fair value of debt derivative liability, related party$409.0K$39.5M
Other income (expense), net-$3.0K-$3.1M
(Loss) income from continuing operations before income taxes-$38.7M$9.5M
Income tax expense-$43.0K-$183.0K
(Loss) income from continuing operations-$38.7M$9.3M
Income from discontinued operations$0$2.7M
Net (loss) income-$38.7M$12.0M
Preferred stock dividends-$3.3M$0
Accretion of preferred stock to redemption value-$192.0K$0
Fair value of conversion ratio improvement to preferred stockholders-$2.1M$0
(Loss) income available to common stockholders-$44.4M$12.0M
(Loss) income from continuing operations available to common stockholders (in dollars per share)-$1$0
Income from discontinued operations (in dollars per share)$0$0
Basic (loss) income per share (in dollars per share)-$1.27$0.39
(Loss) income from continuing operations available to common stockholders (in dollars per share)-$1$0
Income from discontinued operations (in dollars per share)$0$0
Diluted (loss) income per share (in dollars per share)-$1.27$0.33
Basic (in shares)34.8M shares30.5M shares
Diluted (in shares)34.8M shares36.7M shares

Compare LIFECORE BIOMEDICAL, INC. \DE\ with another company

Corporate structure

LIFECORE BIOMEDICAL, INC. \DE\ sits at the top of its group. 5 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LIFECORE BIOMEDICAL, INC. \DE\

  • LIFECORE BIOMEDICAL, INC. \DE\ Chaska, Minnesota
    • Camden Fruit Corp Subsidiary · California, United States
    • Curation Foods, Inc. Subsidiary · Delaware, United States
    • Greenline Logistics, Inc. Subsidiary · Ohio, United States
    • Lifecore Biomedical Operating Company, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LIFECORE BIOMEDICAL, INC. \DE\ reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$186.5M6 Dec 31, 2025$199.5M6 May 26, 2024−6.5%
Accumulated depreciation$59.2M6 Dec 31, 2025$50.3M6 May 26, 2024+17.5%
Property and equipment, net$127.3M6 Dec 31, 2025$149.2M6 May 26, 2024−14.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$17.5M6 Dec 31, 2025$8.5M6 May 26, 2024+106.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$13.9M6 Dec 31, 2025$13.9M6 May 26, 20240%
Intangible assets, net (excluding goodwill)$4.2M2 May 25, 2025$4.2M2 May 26, 20240%
Accumulated amortization$3.7M2 May 25, 2025$3.7M2 May 26, 20240%

Inventory

ItemLatestA year beforeChange
Inventory, total$29.1M6 Dec 31, 2025$40.0M6 May 26, 2024−27.2%
Raw materials$10.1M6 Dec 31, 2025$13.1M6 May 26, 2024−23.2%
Work in process$7.1M6 Dec 31, 2025$11.9M6 May 26, 2024−40.0%
Finished goods$11.8M6 Dec 31, 2025$14.9M6 May 26, 2024−20.6%

Properties, in its own words

As of December 31, 2025, the Company’s principal facilities consist of owned and leased properties used for manufacturing, laboratory, warehouse, and administrative operations. We own a facility in Chaska, Minnesota totaling approximately 148,200 square feet of office, laboratory, and manufacturing space, which together with substantially all of our consolidated assets other than cash, accounts receivable and inventory, secures borrowings under our term loan credit facility.

We also lease facilities in Chaska, Minnesota (approximately 80,950 square feet) and Chanhassen, Minnesota (approximately 21,384 square feet) that support our office, manufacturing, and warehouse activities. The Chaska lease expires in September 2034, and the Chanhassen lease expires in March 2028 with an option to extend through March 2033 that the Company is reasonably certain to exercise. For additional information about lease terms, see “Part IV, Item 15. Note 16 – Leases” of this Annual Report on Form 10-KT.

The rest of Item 2

Collectively, these properties provide adequate and suitable capacity for our current operations. We do not expect difficulties in retaining occupancy through lease renewals or in securing equivalent facilities. We believe our owned and leased facilities are in good condition and suitable for the ongoing conduct of our business.

Item 2 of the 10-KT filed Mar 16, 2026.17

Leadership

Who has led LIFECORE BIOMEDICAL, INC. \DE\, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gary T. Steele2006–2015
  2. Dennis J. Allingham2010
  3. Molly Hemmeter2016–2019
  4. Albert D. Bolles2019–2022
  5. Paul Josephs2024–now

President

  1. Gary T. Steele2006–2015
  2. Dennis J. Allingham2010

Chief financial officer

  1. Gregory S. Skinner2006–2020
  2. John D. Morberg2021–2024
  3. Ryan David Lake2024–now

Chief operating officer

  1. David D. Taft2006–2010
  2. Molly Hemmeter2014–2015
2010201520202025
Board members and other officers (36)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Camden Fruit Corp California4
  • Curation Foods, Inc. Delaware4
  • Greenline Logistics, Inc. Ohio4
  • Lifecore Biomedical Operating Company, Inc. Delaware4
  • Lifecore Biomedical, LLC Minnesota4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • LANDEC CORP \CA\Jun 17, 1996 to Nov 7, 20223

Timeline

  1. Sep 29, 20268-K Entered a material agreement60
  2. Sep 28, 20268-K Entered a material agreement; Regulation FD disclosure61
  3. Aug 5, 20268-K Results of operations; Regulation FD disclosure62
  4. Jul 2, 20268-K Regulation FD disclosure63
  5. Jun 5, 20268-K Executive or director change; Shareholder vote64
  6. May 6, 20268-K Results of operations; Regulation FD disclosure65
  7. Mar 16, 20268-K Results of operations; Regulation FD disclosure66
  8. Mar 5, 20268-K Director nominations67
  9. Jan 16, 20268-K Executive or director change68
  10. Nov 17, 20258-K Regulation FD disclosure69
  11. Nov 6, 20258-K Results of operations; Regulation FD disclosure70
  12. Oct 31, 20258-K Shareholder vote71
  13. May 22, 2024New chief executive Paul Josephs becomes CEO18
  14. May 28, 2019New chief executive Albert D. Bolles becomes CEO19
  15. Mar 24, 2016New chief executive Molly Hemmeter becomes CEO20
  16. May 27, 2010New chief executive Dennis J. Allingham becomes CEO21
  17. Jan 18, 2006New chief executive Gary T. Steele becomes CEO22

Calendar

Coming up

  1. Around Nov 4, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results62
  2. May 6, 2026Reported quarterly or annual results65
  3. Mar 16, 2026Reported quarterly or annual results66
  4. Nov 6, 2025Reported quarterly or annual results70
  5. Aug 7, 2025Reported quarterly or annual results72
  6. Apr 3, 2025Reported quarterly or annual results73
  7. Jan 2, 2025Reported quarterly or annual results74
  8. Oct 4, 2024Reported quarterly or annual results75

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

330 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 84 major events, 129 insider forms, 46 large holders, 49 other. The latest 20:

  1. Sep 29, 2026SCHEDULE 13D/A EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 28, 2026DEFA14A DEFA 14A EDGAR
  4. Sep 28, 20268-K EDGAR
  5. Sep 28, 2026SCHEDULE 13D/A EDGAR
  6. Aug 5, 202610-Q EDGAR
  7. Aug 5, 20268-K EDGAR
  8. Jul 29, 2026SCHEDULE 13G EDGAR
  9. Jul 2, 2026SCHEDULE 13D/A EDGAR
  10. Jul 2, 20268-K EDGAR
  11. Jul 2, 2026SCHEDULE 13D/A EDGAR
  12. Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jun 5, 20264 EDGAR
  14. Jun 5, 20264 EDGAR
  15. Jun 5, 20264 EDGAR
  16. Jun 5, 20264 EDGAR
  17. Jun 5, 20264 EDGAR
  18. Jun 5, 20264 EDGAR
  19. Jun 5, 20264 EDGAR
  20. Jun 5, 20268-K EDGAR

The 330 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 8 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 28, 2025English Aron R.10% ownerSale150,419$7.12$1.1MForm 4
May 27, 2025English Aron R.10% ownerSale1,139,504$6.50$7.4MForm 4
May 23, 2025English Aron R.10% ownerSale96,137$6.75$648.9KForm 4
May 13, 202522NW Fund GP, LLC10% ownerSale12,334$7.00$86.3KForm 4
May 12, 202522NW Fund GP, LLC10% ownerSale45,698$7.03$321.3KForm 4
May 9, 202522NW Fund GP, LLC10% ownerSale700$7.00$4.9KForm 4
May 8, 202522NW Fund GP, LLC10% ownerSale5,098$7.00$35.7KForm 4
May 7, 202522NW GP, Inc.10% ownerSale15,847$7.01$111.1KForm 4
May 6, 202522NW GP, Inc.10% ownerSale701$7.05$4.9KForm 4
May 5, 202522NW GP, Inc.10% ownerSale24,543$7.08$173.8KForm 4
Jan 8, 2025Josephs PaulChief Executive OfficerBuy17,000$5.74$97.6KForm 4
Oct 3, 2024Wynnefield Capital, Inc. Profit Sharing Plan10% ownerBuy292,683$4.10$1.2MForm 4
Oct 3, 2024Legion Partners Asset Management, LLCDirectorBuy1,463,414$4.10$6.0MForm 4
Nov 25, 2022WYNNEFIELD CAPITAL MANAGEMENT LLC10% ownerBuy627,746$7.97$5.0MForm 4
Oct 24, 2022OBUS NELSONDirectorBuy250,000$8.09$2.0MForm 4
Jan 13, 2022WYNNEFIELD PARTNERS SMALL CAP VALUE LP I10% ownerBuy87,400$10.42$910.6KForm 4
Jan 12, 2022Schechter JoshuaDirectorBuy10,000$10.39$103.9KForm 4
Jan 12, 2022WYNNEFIELD PARTNERS SMALL CAP VALUE LP I10% ownerBuy300,000$10.41$3.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 97. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Wynnefield Capital Inc4,703,216$24.7M17.0%No change
Legion Partners Asset Management, LLC4,461,823$23.4M57.8%No change
Greenhaven Road Investment Management, L.P.3,190,769$16.8M10.9%−346,804
325 Capital LLC2,895,881$15.2M3.6%+733,415
BlackRock, Inc.2,013,093$10.6M0.0%+135,788
Vanguard Capital Management LLC1,288,621$6.8M0.0%−1,515
Geode Capital Management, LLC855,500$4.5M0.0%+40,393
Morgan Stanley769,360$4.0M0.0%+4,626
State Street Corp668,031$3.5M0.0%+26,025
Quinn Opportunity Partners LLC453,495$2.4M0.1%No change
DCF Advisers, LLC424,500$2.2M0.6%No change
Wittenberg Investment Management, Inc.314,015$1.6M0.6%+12,200
Northern Trust Corp253,817$1.3M0.0%+25,659
Vanguard Fiduciary Trust Co239,924$1.3M0.0%+2,859
LPL Financial LLC207,300$1.1M0.0%−490
Vanguard Portfolio Management LLC189,073$992.6K0.0%+24,513
Marshall Wace, Llp177,471$931.7K0.0%+119,117
Tocqueville Asset Management L.P.151,700$796.4K0.0%No change
Millennium Management LLC133,305$699.9K0.0%−23,852
Goldman Sachs Group Inc124,940$655.9K0.0%−43,436
Renaissance Technologies LLC104,859$550.5K0.0%New
Grizzlyrock Capital, LLC103,000$540.8K0.4%−724,488
Citadel Advisors LLC98,870$519.1K0.0%New
Allspring Global Investments Holdings, LLC96,589$509.0K0.0%New
Squarepoint Ops LLC92,674$486.5K0.0%+40,270

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How LIFECORE BIOMEDICAL, INC. \DE\ is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLIFECORE BIOMEDICAL, INC. \DE\1
  • CIK0001005286
  • Employer ID (EIN)94-302561817
  • Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsMay 251
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3515 Lyman Boulevard, Chaska, MN 553181
  • Phone95236843001
  • Shares outstanding37,853,060 as of Jul 29, 202614
  • Public float$223.0M as of Jun 30, 202517
  • AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 243; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceFeb 13, 19961
  • Filings1,738 in all: 4 (860), 8-K (278), SC 13G/A (121), 10-Q (91), SC 13G (53), 3 (40), DEF 14A (32), 10-K (29)1
    All 40 form types

    4/A (27), SC 13D/A (26), UPLOAD (26), CORRESP (19), S-8 (16), 8-K/A (11), SC 13D (10), NT 10-Q (7), PRE 14A (7), 424B3 (6), S-3/A (6), SCHEDULE 13D/A (6), 144 (5), 3/A (5), ARS (5), EFFECT (5), S-3 (5), SCHEDULE 13G/A (5), 10-K/A (4), DEFA14A (4), S-8 POS (4), SCHEDULE 13G (4), 5 (3), NT 10-K (3), POS AM (3), S-1 (3), 10-KT (2), 10-Q/A (2), REGDEX (2), 5/A (1), D (1), S-1/A (1)

  • Latest filingsAnnual report (10-KT) Mar 16, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 24, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareLFCRNASDAQ

From the cover page of the 10-KT filed Mar 16, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks LIFECORE BIOMEDICAL, INC. \DE\ names in Item 1A of its 10-KT filed Mar 16, 2026: 30 risks under these headings, as written.17

  • Risks related to our internal controls and financial reporting
  • Risks related to our financial and cash position
  • Risks related to our business and operations
  • Risks related to ownership of our Common Stock
  • General risks
  • We have identified material weaknesses in our internal control over financial reporting that have affected the reliability of our financial statements and have had, and may continue to have, other adverse consequences.
  • We are highly leveraged and subject to significant interest, fair market value fluctuations, and certain credit agreement obligations, some of which are expected to grow. These may negatively impact our results and limit cash flow available to invest in the ongoing needs of our business, as well as our operational flexibility, or otherwise adversely affect our results of operations.
  • We have a history of losses. We may need additional capital and any additional capital we seek may not be available in the amount we need, at the time we need it or on terms favorable to us.
  • Our ability to retain existing customers, attract new customers and sell additional products and services to our existing and new customers, is highly dependent on the actual and perceived stability of our business and financial condition.
  • Customer demand for our products and services is based on many factors that are beyond our control.
  • A significant portion of our revenue has been concentrated on a few large customers, including Alcon, one of our primary lenders, and terminations of agreements or cancellations or delays of orders by these customers may adversely affect our business.
  • We may be adversely impacted by the terms of our refinancing transactions with Alcon and by Alcon’s concentrated relationship with us as a significant customer of ours and as our lender.
The other 23 risks
  • We are subject to increasing competition in the marketplace.
  • Our profitability is dependent upon our ability to obtain appropriate pricing for our products and to control our cost structure or to pass along costs to our customers.
  • Our CDMO services are highly complex, and our failure to provide quality and timely services to our CDMO customers could adversely impact our business.
  • Our customers’ failure to receive or maintain regulatory approval for product candidates or products could negatively impact our revenue and profitability.
  • Our business is highly regulated and our operations are subject to laws, regulations and standards that directly impact our business.
  • Loss or compromise of our HA bacterial cell bank assets could materially impact our business operations, product quality and competitive position.
  • Our development and manufacturing activities may expose us to product liability claims.
  • We have a concentration of facilities and unforeseen events could materially disrupt our ability to provide services and manufacture products for our customers.
  • Our dependence on single-source suppliers and service providers may cause disruption in our operations should any supplier fail to deliver materials.
  • Changes to U.S. trade policy, tariff and import/export regulations may have a material adverse effect on our business.
  • We may need to consider new business acquisitions to achieve our growth strategy, and any such acquisition would involve substantial effort and costs to complete and uncertainty relating to integration.
  • Future resales, or the perception of future resales, of our Common Stock may cause the market price of our Common Stock to drop significantly, even if our business is doing well.
  • Our stock price may fluctuate in response to various conditions, many of which are beyond our control.
  • Our Redeemable Convertible Preferred Stock has rights, preferences, and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.
  • Our stockholders will experience significant dilution as a result of the issuance of shares of our Common Stock upon conversion of the Redeemable Convertible Preferred Stock.
  • Our corporate organizational documents and Delaware law have anti-takeover provisions, and our agreements contain certain provisions, that may inhibit or prohibit a takeover of us and the replacement or removal of our management.
  • The outcome of existing and future litigation and regulatory proceedings and the related fees, costs and penalties could have a material adverse effect on our business.
  • We are dependent on our key employees and if one or more of them were to leave, we could experience difficulties in replacing them or effectively transitioning their replacements and our operating results could suffer.
  • Our reputation and business may be harmed if our computer network security or any of the databases containing our trade secrets, proprietary information or the personal information of our employees, or those of third parties, are compromised.
  • We are implementing a new enterprise resource planning system, and challenges with the implementation of the system may impact our business and operations.
  • Third parties may claim that our services or our customers’ products infringe their intellectual property rights.
  • We have access to certain intellectual property and information of our customers and suppliers, and failure to protect that intellectual property or information could adversely affect our future growth and success.
  • We may be unable to protect our intellectual property and proprietary processes from infringement or claims of ownership or rights by third parties, which could materially and adversely affect the Company.

Legal proceedings

In the ordinary course of business, the Company is involved in various legal proceedings and claims. The information relating to material pending legal proceedings contained in “Part IV, Item 15. Note 9 - Commitments and contingencies” of this Annual Report on Form 10-KT is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88